BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 8680052)

  • 1. Mycophenolate mofetil in liver transplantation.
    McDiarmid SV
    Clin Transplant; 1996 Feb; 10(1 Pt 2):140-5. PubMed ID: 8680052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.
    Moreso F; Serón D; Morales JM; Cruzado JM; Gil-Vernet S; Pérez JL; Fulladosa X; Andrés A; Grinyó JM
    Clin Transplant; 1998 Jun; 12(3):198-205. PubMed ID: 9642510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.
    Hebert MF; Ascher NL; Lake JR; Emond J; Nikolai B; Linna TJ; Roberts JP
    Transplantation; 1999 Mar; 67(5):707-12. PubMed ID: 10096526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia.
    Hao C; Anwei M; Bing C; Baiyong S; Weixia Z; Chuan S; Erzhen C; Xiaxing D; Weihua Q; Weiping Y; Chenghong P; Hongwei L
    Liver Transpl; 2008 Aug; 14(8):1165-73. PubMed ID: 18668650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
    Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
    Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Klupp J; Glanemann M; Junge G; Pfitzmann R; Bahra M; Radtke C; Neumann U; Neuhaus R; Neuhaus P
    Clin Transplant; 2006; 20(3):272-83. PubMed ID: 16824141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial.
    Sterneck M; Fischer L; Gahlemann C; Gundlach M; Rogiers X; Broelsch C
    Ann Transplant; 2000; 5(1):43-6. PubMed ID: 10850611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of mycophenolate mofetil on recurrent rejection in kidney transplant patients.
    Vasquez EM; Sifontis NM; Pollak R; Benedetti E
    Clin Transplant; 2001 Aug; 15(4):253-7. PubMed ID: 11683819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
    Stegall MD; Wachs ME; Everson G; Steinberg T; Bilir B; Shrestha R; Karrer F; Kam I
    Transplantation; 1997 Dec; 64(12):1755-60. PubMed ID: 9422416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
    Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis.
    Trouillot TE; Shrestha R; Kam I; Wachs M; Everson GT
    Liver Transpl Surg; 1999 Sep; 5(5):375-80. PubMed ID: 10477838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
    J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.